EUVIMEDEUVIMED entdecken
BeobachtungsstudieFallberichtOpen Access · CC BY 4.0

Clinical spectrum of extreme insulin resistance syndromes treated with rhIGF-1: A single-center experience

Nicola Improda iD, Harshini Katugampola iD, Manuela Cerbone, Pratik Shah iD, Saji Alexander, Abigail Atterbury, Smail Hadj-Rabia iD, Catherine J Peters, Robert K Semple, Mehul Tulsidas Dattani iD

The Journal of Clinical Endocrinology & Metabolism · 17.06.2026 · 111 (7) · 2049-2063

DOI: 10.1210/clinem/dgag031 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 28.01.2026. Verfasst von Nicola Improda und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Department, Neuroendocrine and Obesity Centre, Santobono-Pausilipon Children's Hospital, Naples 80139, Italy. Hauptthemen laut MEDLINE: Insulin Resistance, Insulin-Like Growth Factor I, Donohue Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Donohue syndrome (DS) and Rabson-Mendenhall syndrome (RMS) are extreme forms of insulin resistance (IR) caused by biallelic mutations in the insulin receptor gene. Recombinant human insulin-like growth factor-1 (rhIGF-1) treatment is often used but its long-term benefits and risks are still poorly delineated.

Objective

We describe rhIGF-1 treatment outcomes of a cohort of patients with DS and RMS, and compare them to previously published patients.

Methods

A single-center retrospective observational study with case note review was conducted. A literature search was performed for previously published DS and RMS patients treated with rhIGF-1. Results rhIGF-1 outcomes beyond 4 months have been reported for only 11 patients with DS and RMS to date. We provide outcome data for 3 more males, and report the long-term clinical course of a patient already described. Metabolic benefits of rhIGF-1 included improved glycemic control and fasting tolerance in early years of life, and some growth enhancement. Two patients exhibited poor response or intolerance to rhIGF-1 and died in infancy. The 2 longest-lived patients had progressive decompensation to diabetes mellitus, in 1 case despite long-term uninterrupted rhIGF-1 therapy. We also describe new features associated with severe insulin receptoropathies, such as cataract, liver hemangioma, and impaired hepatic protein synthesis.

Conclusion

The phenotypes of DS and RMS are heterogeneous. Current treatment options remain unsatisfactory as high-dose rhIGF-1 exerts only limited beneficial effects and does not prevent decompensation to diabetes mellitus. More research is needed to identify alternative treatment strategies for extreme forms of IR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistanceInsulin-Like Growth Factor IDonohue SyndromeHumansMaleRetrospective StudiesRecombinant ProteinsFemaleChild, PreschoolTreatment OutcomeChildInfantAdolescent

Stichwörter der Autor:innen

Donohue syndromeRabson-Mendenhall syndromediabetes mellitushyperinsulinemic hyperglycemiainsulin resistancerecombinant human insulin-like growth factor-1

Substanzen

Insulin-Like Growth Factor IRecombinant Proteins

Autor:innen und Institutionen

  • Neuroscience Department, Neuroendocrine and Obesity Centre, Santobono-Pausilipon Children's Hospital, Naples 80139, Italy.
  • Department of Medical Translational Sciences, Federico II University of Naples, Naples 80131, Italy.
  • London Centre for Paediatric Endocrinology and Diabetes at Great Ormond Street Children's Hospital, London WC1N 1EH, UK.
  • Section of Molecular Basis of Rare Disease, Genetics and Genomic Medicine Research and Teaching Department, University College London Great Ormond Street Hospital Institute of Child Health, London WC1N 1EH, UK.
  • Paediatric Endocrinology Department, The Royal London Children's Hospital and Queen Mary University of London, Barts Health NHS Trust, London E1 1BB, UK.
  • Department of Paediatric Endocrinology and Diabetes, Chelsea and Westminster NHS Foundation Trust, London SW10 9NH, UK.

ORCID-Profile: Nicola Improda, Harshini Katugampola, Pratik Shah, Smail Hadj-Rabia, Mehul Tulsidas Dattani

Zitieren

APA

Improda, N., Katugampola, H., Cerbone, M., Shah, P., Alexander, S., Atterbury, A., Hadj-Rabia, S., Peters, C. J., Semple, R. K., & Dattani, M. T. (2026). Clinical spectrum of extreme insulin resistance syndromes treated with rhIGF-1: A single-center experience. The Journal of Clinical Endocrinology & Metabolism, 111(7), 2049-2063. https://doi.org/10.1210/clinem/dgag031

Vancouver

Improda N, Katugampola H, Cerbone M, Shah P, Alexander S, Atterbury A, et al. Clinical spectrum of extreme insulin resistance syndromes treated with rhIGF-1: A single-center experience. The Journal of Clinical Endocrinology & Metabolism. 2026;111(7):2049-2063. doi:10.1210/clinem/dgag031

BibTeX
@article{Improda2026,
  author = {Improda, Nicola and Katugampola, Harshini and Cerbone, Manuela and Shah, Pratik and Alexander, Saji and Atterbury, Abigail and Hadj-Rabia, Smail and Peters, Catherine J and Semple, Robert K and Dattani, Mehul Tulsidas},
  title = {Clinical spectrum of extreme insulin resistance syndromes treated with rhIGF-1: A single-center experience},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {7},
  pages = {2049--2063},
  doi = {10.1210/clinem/dgag031}
}
Kostenlos starten →